Last reviewed · How we verify

NCT03949231

Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

Recruiting now Phase 3 Last updated 26 June 2024
What this trial tests

Phase 3 trial testing PD1/PDL1 inhibitor in Liver Cancer in 200 participants. Currently enrolling.

Timeline
1 January 2019
Primary endpoint
1 January 2029
2 January 2038

Quick facts

Lead sponsorSecond Affiliated Hospital of Guangzhou Medical University
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment200
Start date1 January 2019
Primary completion1 January 2029
Estimated completion2 January 2038
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Who can join

Adults 18 to 80, any sex, with Liver Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial was designed to investigate the survival outcomes, response rates, and safety of patients with Barcelona-Clinical Hepatocellular Carcinoma (BCLC)-C-stage liver cancer by hepatic artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Immunologic tumor microenvironment modulators for turning cold tumors hot.
    Khosravi GR, Mostafavi S, Bastan S, Ebrahimi N, et al · · 2024 · cited 182× · PMID 38551889 · DOI 10.1002/cac2.12539
  2. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
    Giraud J, Chalopin D, Blanc JF, Saleh M. · · 2021 · cited 172× · PMID 33815418 · DOI 10.3389/fimmu.2021.655697
  3. Inflammatory Mechanisms of HCC Development.
    Refolo MG, Messa C, Guerra V, Carr BI, et al · · 2020 · cited 149× · PMID 32164265 · DOI 10.3390/cancers12030641
  4. Hepatocellular carcinoma: signaling pathways and therapeutic advances.
    Zheng J, Wang S, Xia L, Sun Z, et al · · 2025 · cited 142× · PMID 39915447 · DOI 10.1038/s41392-024-02075-w
  5. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.
    Xu L, Zou C, Zhang S, Chu TSM, et al · · 2022 · cited 131× · PMID 35799264 · DOI 10.1186/s13045-022-01307-2
  6. [Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)].
    Department of Medical Administration, National Health and Health Commission of the People's Republic of China. · · 2020 · cited 116× · PMID 32164061 · DOI 10.3760/cma.j.issn.1007-3418.2020.02.004
  7. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
    Liu Z, Liu X, Liang J, Liu Y, et al · · 2021 · cited 109× · PMID 34675942 · DOI 10.3389/fimmu.2021.765101
  8. Immune Checkpoint Inhibitors in the Treatment of HCC.
    Donisi C, Puzzoni M, Ziranu P, Lai E, et al · · 2020 · cited 105× · PMID 33585218 · DOI 10.3389/fonc.2020.601240

Verify or expand the search:

Other recruiting trials for Liver Cancer

Currently open trials in the same condition.

Other Second Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03949231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing